Carnitine (L-carnitine, L-carnitine L-tartrate, acetyl-L-carnitine) trials recruiting now
9 registrations that name carnitine as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 9 registrations
Status
Phase
3US sites across 2 states
1
2 to 4
5 to 19
20 or more
All 9 registrations
RecruitingNCT06845046
A Study to Improve Skeletal Muscle in Veterans With HIV
No phase
VA Office of Research and Development
About 70 people
Started Jul 15, 2025
In plain words A study of carnitine in male participants 20 to 80, run by VA Office of Research and Development. It plans to enroll about 70 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists male participants 20 to 80. Conditions: HIV; Obesity.
Veteran
HIV+
antiretroviral therapy = integrase strand transfer inhibitor for at least 3 months
HIV-1 RNA <50 copies/ml
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
w-3 fatty acid; L-carnitine; Control Diet
Registered summary
The Department of Veterans Affairs is the largest single provider of medical care to people with HIV in the United States. The condition of excess lipid within and around muscle, termed myosteatosis, predisposes Veterans to physical function decline, frailty, disability, and cardiometabolic diseases such as diabetes and cardiovascular disease. In the investigators current Merit supported cohort, the investigators found that 36% of Veterans with treated HIV and obesity have "myosteatotic type obesity". The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT07437391
Effect of L-Carnitine Supplementation in Preterm Neonates
No phase
Muhammad Aamir Latif
About 160 people
Started Jan 1, 2026
In plain words A study of carnitine in people 1 hour to 24 hours, run by Muhammad Aamir Latif. It plans to enroll about 160 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 1 hour to 24 hours. Conditions: Respiratory Distress Syndrome.
Preterm neonates
Either gender
With RDS
Admitted to the neonatal intensive care unit (NICU) within 24 hours of birth .
The exclusion criteria are on the listing.
What it tests, as registered
L-carnitine; Standard care
Registered summary
The current study is planned to see the effect of L-carnitine supplementation in preterm neonates suffering from RDS among the local population, as there is no such evidence available for the local population and there are conflicting statistics regarding the discharge rate of these neonates.
Where, as registered
No US site; Pakistan (1).
RecruitingNCT07298564
Effect of Magnesium and Levocarnitine on Metabolic and Clinical Outcomes in Women With Polycystic Ovarian Syndrome (PCOS)
No phase
Behnood Abbasi
About 84 people
Starts Jan 30, 2026 (estimated)
In plain words A study of carnitine in female participants 19 to 65, run by Behnood Abbasi. It plans to enroll about 84 people at 1 site, none in the US.
Polycystic Ovary Syndrome (PCOS) is one of the most common endocrine disorders among women of reproductive age and is associated with metabolic abnormalities such as insulin resistance, dyslipidemia, and hormonal imbalance, which may lead to infertility and hirsutism. Despite the availability of several pharmacological treatments, many therapies fail to effectively address the underlying metabolic and endocrine dysfunctions of PCOS. The full summary is on the listing.
Where, as registered
No US site; Iran (1).
RecruitingNCT07783399
The Effects of Carnitine Supplementation on Oocytes in Women Undergoing IVF Process
No phase
The Obstetrics and Gynaecology Clinic Narodni Front
About 70 people
Started May 15, 2026
In plain words A study of carnitine in female participants 18 to 45, run by The Obstetrics and Gynaecology Clinic Narodni Front. It plans to enroll about 70 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 to 45. Conditions: Infertility (IVF Patients).
women undergoing IVF process
women aged 18-45 years
The exclusion criteria are on the listing.
What it tests, as registered
L-Carnitine Group
Registered summary
The goal of this clinical trial is to learn whether supplementation with L-carnitine improves outcomes in women undergoing in vitro fertilization (IVF). It will also evaluate the effect of supplementation on oocyte quality, embryo quality, and pregnancy rates. The full summary is on the listing.
Where, as registered
No US site; Serbia (1).
RecruitingNCT06753565
L-carnitine Supplementation in Rheumatoid Arthritis Patients
Phase 2
German University in Cairo
About 60 people
Started Dec 31, 2024
In plain words A Phase 2 study of carnitine in people 18 to 60, run by German University in Cairo. It plans to enroll about 60 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 60. Conditions: Rheumatoid Arthritis (RA).
age between 18-60 years old
diagnosed of rheumatoid arthritis according to 2010 American College of Rheumatology/European League Against Rheumatism criteria for at least 6 months
enrolled patients treated with one of more of conventional DMARDs for ≥ 6 months with stable dose for ≥ 1 month before start of the study
active RA despite conventional DMARDs treatment (DAS28 ESR more than or equal 3.2)
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Carnitine; Disease-modifying anti-rheumatic drugs
Registered summary
This study aims to evaluate the effect of l-carnitine as add- on therapy for improving the outcome in rheumatoid arthritis patients.
Where, as registered
No US site; Egypt (1).
RecruitingNCT07108777
L-Carnitine Protective Effect in Nephrotoxicity
Phase 2
Tanta University
About 46 people
Started Aug 10, 2025
In plain words A Phase 2 study of carnitine in people 18 to 75, run by Tanta University. It plans to enroll about 46 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 75. Conditions: Nephrotoxicity.
Male or female patients.
Newly diagnosed patients with cancer and with an indication for cisplatin - based chemotherapy.
Age between 18 and 75 years.
No serious cardiopulmonary comorbidity which could impair involvement in the study.
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
L-Carnitine Tartrate; Placebo
Registered summary
The goal of this clinical trial is to assess the possible reno-protective effect of L-carnitine against cisplatin-induced nephrotoxicity in patients receiving cisplatin-based chemotherapy. The main question it aims to answer is: Does L-carnitine have the ability to protect the kidney against cisplatin-induced nephrotoxicity?
Where, as registered
No US site; Egypt (1).
RecruitingNCT07201714
Oral Carnitine in Heart Failure Patients
Early phase 1
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
About 20 people
Started Nov 12, 2025
In plain words An early phase 1 study of carnitine in people 18 and older, run by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's. It plans to enroll about 20 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Heart Failure; Carnitine Deficiency.
Clinical-pathological diagnosis of heart failure with some degree of cardiorenal syndrome
Stage 1, 2, 3a, 3b, or 4 chronic kidney disease
Age ≥ 18 years
Able to speak and read English
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Levocarnitine
Registered summary
Heart failure is a condition in which the heart is unable to pump blood effectively, leading to symptoms like being more tired, shortness of breath, and swelling in the body. Carnitine is a naturally occurring substance in the body that plays a role in turning fat into energy. This study will determine whether oral L-Carnitine supplementation can improve symptoms, enhance heart function and possibly improve the quality of life in individuals with heart failure.
Where, as registered
No US site; Canada (1).
Not yet recruitingNCT07216001
Role of Omega-DEK in Childhood Apraxia of Speech
Phase 2
Claudia R. Morris
About 34 people
Starts Nov 2026 (estimated)
In plain words A Phase 2 study of carnitine in people 36 months to 6, run by Claudia R. Morris. It plans to enroll about 34 people at 2 US sites.
Who it lists and where
Who the trial lists, as registered
Lists people 36 months to 6. Conditions: Childhood Apraxia of Speech; Verbal Apraxia; Autism.
Confirmed diagnosis of childhood apraxia of speech/verbal apraxia by a qualified professional (SLP) based on established guidelines
Male and female, age 36 months - 6 years (inclusive)
Ability to comprehend and use Standard American English
The exclusion criteria are on the listing.
What it tests, as registered
Omega-DEK; L-carnitine; Placebo
Registered summary
This is a 20-week study for children between 3 and 6 years old with confirmed childhood apraxia of speech (CAS). The study includes a 12-week open-label pilot feasibility study of an investigational drug (Omega-DEK) plus L-carnitine (Carnitor®), which is followed by an 8-week randomized, placebo-controlled discontinuation period among the same study participants.
Where, as registered
2 US sites in 1 state.
Not yet recruitingNCT07035444
Enteral Nutrition With L-Carnitine for Cachexia in Non-Small Cell Lung Cancer
No phase
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
About 126 people
Starts Jun 30, 2025 (estimated)
In plain words A study of carnitine in people 18 and older, run by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University. It plans to enroll about 126 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Non-Small Cell Lung Cancer; Cachexia.
1\. Primary lung tumor confirmed by cytology or histology; 2.Meeting the diagnostic criteria for cachexia (with one of the following criteria):
Weight loss >5% in the past 6 months (without active weight loss);
Body mass index (BMI) <20 and weight loss >2%;
Decreased total skeletal muscle index (detected by bioelectrical impedance analysis: <7.26 kg/m² for males; <5.45 kg/m² for females) and weight loss >2%; 3.Age ≥18 years; 4.Patients scheduled to receive or currently undergoing…
7 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
L-Carnitine 4g; Enteral Nutrition
Registered summary
This is a multicenter, double-blind randomized controlled clinical study designed to evaluate the efficacy and safety of oral nutritional supplements (ONS) containing levocarnitine for cachexia in lung cancer patients scheduled for or undergoing chemotherapy. Study Design: Recruitment: Approximately 126 pathologically confirmed patients meeting the inclusion criteria will be enrolled across four hospitals (Army Characteristic Medical Center, Chongqing Fifth People's Hospital, Chongqing Thirteenth People's Hospital, and Chongqing Qianjiang District Central Hospital). The full summary is on the listing.